

Table S4. Function and effect of aberration of SCNV genes associated with cribriform morphology.

Gene	Name	Locus	Functional Role	Aberration in Pca	Reference
Tumor suppressor Genes (TSG)					
TUSC3	Tumor suppressor candidate 3	8p22	Protein N-glycosylation	Initiation & progression	(1)
NKX3-1	NK3 homeobox 1	8p21.2	Inhibits cell proliferation	Hormonal resistance Metastasis & BCR	(2,3)
MAP3K7	Mitogen-Activated Protein Kinase 7	6q15	Cell growth, differentiation and apoptosis	Early BCR Prevention of ERG-fusions	(4,5)
SPOP	Speckle-Type POZ Protein	17q21	DNA repair	Sensitization to PARP inhibitor Resistance to CDC20 inhibitors	(6,7)
ATM	Ataxia Telangiectasia Mutated		DNA-repair	Genomic instability Sensitization to PARP inhibitor	(8)
Proto-oncogenes					
GATA2	Endothelial transcription factor GATA-2	3q21.3	Regulation of transcription	Increases motility, invasiveness, proliferation & resistance to therapies.	(9)
PIK3CA & PIK3CB	PI3K-Alpha & PI3K-Beta	3q26.3 & 3q22.3	PI3K pathway activation	CRPC, proliferation & cell survival	(10,11)
PRKCI	Protein Kinase C Iota	3q26.3	Serine/threonine protein kinase	Enhances cell growth by IL-6	(12)

Abbreviations: PCa, prostate carcinoma; SCNV, Somatic copy number variation; GS, Gleason score; BCR, Biochemical recurrence; CRPC, Castration Resistant Prostate Cancer; PARP, poly(ADP-ribose) polymerase.

References

1. Horak P, Tomasich E, Vanhara P, Kratochvilova K, Anees M, Marhold M, *et al.* TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo. *Scientific reports* **2014**;4:3739
2. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, *et al.* Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. *Cancer research* **2006**;66:10683-90
3. Kluth M, Amschler NN, Galal R, Möller-Koop C, Barrow P, Tsourlakis MC, *et al.* Deletion of 8p is an independent prognostic parameter in prostate cancer. *Oncotarget* **2017**;8:379-92
4. Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, *et al.* Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* **2013**;26:975-83
5. Kluth M, Meyer D, Krohn A, Freudenthaler F, Bauer M, Salomon G, *et al.* Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. *Oncotarget* **2016**;7:3897-904
6. Boysen G, Barbieri CE, Prandi D, Blattner M, Chae SS, Dahija A, *et al.* SPOP mutation leads to genomic instability in prostate cancer. *eLife* **2015**;4
7. Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades N, *et al.* Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. *Cancer letters* **2017**;385:207-14
8. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, *et al.* DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *The New England journal of medicine* **2015**;373:1697-708

9. Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J. The role of GATA2 in lethal prostate cancer aggressiveness. *Nature reviews Urology* **2017**;14:38-48
10. Agell L, Hernandez S, Salido M, de Muga S, Juanpere N, Arumi-Uria M, *et al.* PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* **2011**;24:443-52
11. Hill KM, Kalifa S, Das JR, Bhatti T, Gay M, Williams D, *et al.* The role of PI 3-kinase p110beta in AKT signalling, cell survival, and proliferation in human prostate cancer cells. *The Prostate* **2010**;70:755-64
12. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y, *et al.* aPKC λ /iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. *Proceedings of the National Academy of Sciences of the United States of America* **2009**;106:16369-74